Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.

The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study. The percentage of patients with no emetic episodes over the 3-day study period was 61% in the ondansetron BID group compared with 58% in the ondansetron TID group. Among patients with at least one emetic episode, the mean time to emesis was 14 hr and 17 min in the ondansetron BID group compared with 12 hr and 48 min in the ondansetron TID group. Patients' daily appetite ratings and nausea scores were not significantly different between groups. Clinical laboratory and adverse event profiles were similar between groups. This study is the first large-scale, double-blind trial to demonstrate that ondansetron 8 mg BID for 3 days, a dosing regimen that may enhance patient convenience and compliance, is as effective as ondansetron 8 mg TID for 3 days in the prevention of nausea and vomiting associated with cyclophosphamide-based chemotherapy.

[1]  B. O'brien,et al.  Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  A. Ciociola,et al.  Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based Chemotherapy , 1993, Annals of Internal Medicine.

[3]  J. Hainsworth,et al.  Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Beck.  Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. , 1992, Seminars in oncology.

[5]  C. Lindley,et al.  Nausea and vomiting and cancer patients' quality of life: a discussion of Professor Selby's paper. , 1992, The British journal of cancer. Supplement.

[6]  Schmidt Gm.  Prophylaxis of cytomegalovirus infection after bone marrow transplantation. , 1992 .

[7]  S. Sagar.  The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control. , 1991, Cancer treatment reviews.

[8]  J. Hainsworth,et al.  A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Cubeddu,et al.  Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Cubeddu,et al.  Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. , 1990, The New England journal of medicine.

[11]  C. Lindley,et al.  Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[13]  C. McArdle,et al.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. , 1979, British medical journal.